Patents by Inventor Martin E Cooper

Martin E Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS
    Publication number: 20220274938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 1, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Martin BROCH-LIPS, Martin E COOPER, Marc LABELLE, Thomas Holm PEDERSEN, Dastagiri DUDEKULA, Neerja SARASWAT, Rafiq A TAJ
  • Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
    Patent number: 6306863
    Abstract: Compounds of the formula W, Q, R1, R2 and R10 are as defined in the specification. A process for their preparation and pharmaceutical compositions and methods of treatment involving their use in the treatment of respiratory disease including, for example, asthma, are also provided.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: October 23, 2001
    Assignee: AstraZeneca AB
    Inventors: Martin E Cooper, David R Cheshire, David K Donald, Mark Furber, Matthew W. D Perry, Richard P Harrison, Nicholas P Tomkinsson
  • Pyrrolo(3,4-d)pyrimidinone derivatives and their use as medicaments
    Patent number: 6211368
    Abstract: Process for preparing 5-substituted pyrrolo [3,4-d] pyrimidine-2-4-diones of formula (I) wherein W, Q, R1, R2 and R10 are as defined in the specification and Y is COOH, wherein a corresponding C1-5 alkyl ester compound is hydrolyzed. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: April 3, 2001
    Assignee: AstraZeneca UK Limited
    Inventors: Martin E Cooper, David R Cheshire, David K Donald, Mark Furber, Matthew W. D Perry, Richard P Harrison, Nicholas P Tomkinsson
  • Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments
    Patent number: 6166206
    Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: December 26, 2000
    Assignee: AstraZeneca UK Limited
    Inventors: Martin E Cooper, David R Cheshire, David K Donald, Mark Furber, Matthew W. D Perry, Richard P Harrison, Nicholas P Tomkinsson
  • Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments
    Patent number: 6136974
    Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: October 24, 2000
    Assignee: AstraZeneca UK Limited
    Inventors: Martin E Cooper, David R Cheshire, David K Donald, Mark Furber, Matthew W.D Perry, Richard P Harrison, Nicholas P Tomkinsson
  • Pyrrolo[3,4-D] pyrimidinone derivatives and their use as medicaments
    Patent number: 6046204
    Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: April 4, 2000
    Assignee: Astra Pharmaceuticals Limited
    Inventors: Martin E Cooper, David R Cheshire, David K Donald, Mark Furber, Matthew W.D Perry, Richard P Harrison, Nicholas P Tomkinsson